<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780675</url>
  </required_header>
  <id_info>
    <org_study_id>M12PHA</org_study_id>
    <secondary_id>unknown</secondary_id>
    <nct_id>NCT01780675</nct_id>
  </id_info>
  <brief_title>Hippocampus Avoidance PCI vs PCI</brief_title>
  <acronym>HA-PCI vs PCI</acronym>
  <official_title>Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using Intensity Modulated radiotherapy it is possible to treat the entire brain to standard
      dosages of whole-brain radiation, while keeping the radiation dose to the hippocampus low.
      However, a clear relationship between radiation dose and damage to the hippocampal stem
      cells has not been established yet.

      This study is initiated to investigate the early and delayed neurotoxicity of PCI and to
      assess in a randomised design the benefits and risks of sparing the hippocampus in Small
      Cell Lung Cancer patients who receive PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>neurocognitive decline</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Each patient's total recall score recorded at 4 months will be compared to baseline and dichotomized into success (decline less or equal 5 points) or failure (decline more than 5 points). The difference between the groups, in terms of dichotomized decline will be tested by means of the Fisher's exact test. A p-value less than 0.049 will be considered significant. The primary analysis will be based on an intention-to-treat principle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Brain metastases Time from randomization to the occurrence of brain metastases will be calculated and depicted in a cumulative incidence plot. Sensitivity analysis will be performed to assess the value of PCI vs HA-PCI treatment once considering patients dying without distant brain metastases to be censored and once using competing risk analysis considering distant metastases and death as separate events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hippocampal Avoidance PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Prophylactic Cranial Irradiation</intervention_name>
    <arm_group_label>Prophylactic Cranial Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Hippocampal Avoidance PCI</intervention_name>
    <arm_group_label>Hippocampal Avoidance PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  − Small Cell Lung Cancer patients (stage I-III or stage IV without clinical or
             radiological evidence of brain metastases) candidate for PCI, i.e. without
             progressive disease after chemo-radiotherapy in stage I-III or after a remission
             after chemotherapy in stage IV

               -  Sufficient proficiency in Dutch

        Exclusion Criteria:

          -  Prior radiotherapy to the brain

          -  Clinical evidence for brain metastases or primary brain tumors− Evidence of
             progressive extracranial metastatic disease

          -  Previous malignancy &lt; 2 years ago except for adequately treated basal cell carcinoma
             of the skin and carcinoma in situ of the cervix

          -  Any systemic anticancer treatment during PCI or within 3 weeks before start PCI

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <phone>+31 20 512 2174</phone>
    <email>j.belderbos@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanne Schagen, PhD</last_name>
    <phone>+ 31 20 512 2328</phone>
    <email>s.schagen@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <phone>+31 20 512 2135</phone>
      <email>j.belderbos@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sanne Schagen, PhD</last_name>
      <phone>+31 20 512 2328</phone>
      <email>s.schagen@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katrien de Jaeger, MD, PhD</last_name>
      <phone>+31 40 239 6400</phone>
      <email>katrien.d.jaeger@catharinaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Katrien de Jaeger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylactic Cranial Irradiation</keyword>
  <keyword>Hippocampal Avoidance Prophylactic Cranial Irradiation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
